# A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

> **NCT03336333** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **BeiGene** · enrollment: 590 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma

## Interventions

- **DRUG:** Zanubrutinib
- **DRUG:** Bendamustine
- **DRUG:** Rituximab
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03336333
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-10-31
- **Primary completion:** 2021-05-07
- **Final completion:** 2027-10-31
- **Target enrollment:** 590 (ACTUAL)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03336333

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03336333, "A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03336333. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*